M J Sculpher

Summary

Affiliation: University of York
Country: UK

Publications

  1. ncbi request reprint Establishing the cost-effectiveness of new pharmaceuticals under conditions of uncertainty--when is there sufficient evidence?
    Mark Sculpher
    Centre for Health Economics, University of York, York, UK
    Value Health 8:433-46. 2005
  2. pmc Clinical evaluation of magnetic resonance imaging in coronary heart disease: the CE-MARC study
    John P Greenwood
    Division of Cardiovascular and Neuronal Remodelling, Leeds Institute of Genetics, Health and Therapeutics, University of Leeds, Leeds General Infirmary, Leeds, LS1 3EX, UK
    Trials 10:62. 2009
  3. ncbi request reprint Whither trial-based economic evaluation for health care decision making?
    Mark J Sculpher
    Centre for Health Economics, University of York, UK
    Health Econ 15:677-87. 2006
  4. ncbi request reprint Analysis sans frontières: can we ever make economic evaluations generalisable across jurisdictions?
    Mark J Sculpher
    Centre for Health Economics, University of York, York, England
    Pharmacoeconomics 24:1087-99. 2006
  5. pmc Patients' preferences for the management of non-metastatic prostate cancer: discrete choice experiment
    Mark Sculpher
    Centre for Health Economics, University of York, Heslington, York YO10 5DD
    BMJ 328:382. 2004
  6. pmc Cost effectiveness analysis of laparoscopic hysterectomy compared with standard hysterectomy: results from a randomised trial
    Mark Sculpher
    Centre for Health Economics, University of York, Heslington, York YO10 5DD
    BMJ 328:134. 2004
  7. ncbi request reprint Measuring costs and consequences in economic evaluation in asthma
    M J Sculpher
    Centre for Health Economics, University of York, Heslington, York, UK
    Respir Med 97:508-20. 2003
  8. ncbi request reprint Subgroups and heterogeneity in cost-effectiveness analysis
    Mark Sculpher
    Centre for Health Economics and NICE Decision Support Unit, University of York, Heslington, York, UK
    Pharmacoeconomics 26:799-806. 2008
  9. doi request reprint Fondaparinux versus Enoxaparin in non-ST-elevation acute coronary syndromes: short-term cost and long-term cost-effectiveness using data from the Fifth Organization to Assess Strategies in Acute Ischemic Syndromes Investigators (OASIS-5) trial
    Mark J Sculpher
    Centre for Health Economics, University of York, York, United Kingdom Oxford Outcomes Ltd, Oxford, United Kingdom
    Am Heart J 157:845-52. 2009
  10. ncbi request reprint Shared treatment decision making in a collectively funded health care system: possible conflicts and some potential solutions
    Mark Sculpher
    Centre for Health Economics, University of York, Heslington, UK
    Soc Sci Med 54:1369-77. 2002

Detail Information

Publications37

  1. ncbi request reprint Establishing the cost-effectiveness of new pharmaceuticals under conditions of uncertainty--when is there sufficient evidence?
    Mark Sculpher
    Centre for Health Economics, University of York, York, UK
    Value Health 8:433-46. 2005
    ....
  2. pmc Clinical evaluation of magnetic resonance imaging in coronary heart disease: the CE-MARC study
    John P Greenwood
    Division of Cardiovascular and Neuronal Remodelling, Leeds Institute of Genetics, Health and Therapeutics, University of Leeds, Leeds General Infirmary, Leeds, LS1 3EX, UK
    Trials 10:62. 2009
    ....
  3. ncbi request reprint Whither trial-based economic evaluation for health care decision making?
    Mark J Sculpher
    Centre for Health Economics, University of York, UK
    Health Econ 15:677-87. 2006
    ..It is argued that RCT evidence, with or without economic content, should be viewed as simply one of the sources of evidence, which must be placed in a broader framework of evidence synthesis and decision analysis...
  4. ncbi request reprint Analysis sans frontières: can we ever make economic evaluations generalisable across jurisdictions?
    Mark J Sculpher
    Centre for Health Economics, University of York, York, England
    Pharmacoeconomics 24:1087-99. 2006
    ..Expected value of information analyses are also emerging as a tool that could be considered by decision makers to guide their policy on the acceptance or non-acceptance of data from other jurisdictions...
  5. pmc Patients' preferences for the management of non-metastatic prostate cancer: discrete choice experiment
    Mark Sculpher
    Centre for Health Economics, University of York, Heslington, York YO10 5DD
    BMJ 328:382. 2004
    ..To establish which attributes of conservative treatments for prostate cancer are most important to men...
  6. pmc Cost effectiveness analysis of laparoscopic hysterectomy compared with standard hysterectomy: results from a randomised trial
    Mark Sculpher
    Centre for Health Economics, University of York, Heslington, York YO10 5DD
    BMJ 328:134. 2004
    ..To assess the cost effectiveness of laparoscopic hysterectomy compared with conventional hysterectomy (abdominal or vaginal)...
  7. ncbi request reprint Measuring costs and consequences in economic evaluation in asthma
    M J Sculpher
    Centre for Health Economics, University of York, Heslington, York, UK
    Respir Med 97:508-20. 2003
    ..It is concluded that, given the heterogeneity in decision-makers' objectives and constraints, economic studies should be planned and executed in such a way as to maximize flexibility in how results are presented...
  8. ncbi request reprint Subgroups and heterogeneity in cost-effectiveness analysis
    Mark Sculpher
    Centre for Health Economics and NICE Decision Support Unit, University of York, Heslington, York, UK
    Pharmacoeconomics 26:799-806. 2008
    ..A major issue also exists concerning the appropriateness, in terms of equity, of using all or some of the subgroup analyses as a basis of decision making. NICE needed to consider these and other issues when updating its methods guidance...
  9. doi request reprint Fondaparinux versus Enoxaparin in non-ST-elevation acute coronary syndromes: short-term cost and long-term cost-effectiveness using data from the Fifth Organization to Assess Strategies in Acute Ischemic Syndromes Investigators (OASIS-5) trial
    Mark J Sculpher
    Centre for Health Economics, University of York, York, United Kingdom Oxford Outcomes Ltd, Oxford, United Kingdom
    Am Heart J 157:845-52. 2009
    ..The study aimed to compare the short-term costs and long-term cost-effectiveness of 2 antithrombotics, fondaparinux and enoxaparin, for non-ST-elevation acute coronary syndrome in the United States...
  10. ncbi request reprint Shared treatment decision making in a collectively funded health care system: possible conflicts and some potential solutions
    Mark Sculpher
    Centre for Health Economics, University of York, Heslington, UK
    Soc Sci Med 54:1369-77. 2002
    ..It argues that the risk of conflict may be reduced by making a clear distinction between clinical guidelines (focusing on effectiveness) and system guidelines (focusing on cost-effectiveness)...
  11. ncbi request reprint Recognizing diversity in public preferences: the use of preference sub-groups in cost-effectiveness analysis
    M Sculpher
    Centre for Health Economics, University of York, York, UK
    Health Econ 10:317-24. 2001
    ....
  12. ncbi request reprint Low doses vs. high doses of the angiotensin converting-enzyme inhibitor lisinopril in chronic heart failure: a cost-effectiveness analysis based on the Assessment of Treatment with Lisinopril and Survival (ATLAS) study. The ATLAS Study Group
    M J Sculpher
    Centre for Health Economics, University of York, Helsington, York, YO10 5DD, UK
    Eur J Heart Fail 2:447-54. 2000
    ..A cost-effectiveness analysis of high and low doses of the angiotensin-converting enzyme (ACE) inhibitor lisinopril in the treatment of chronic heart failure...
  13. ncbi request reprint Income effects of reduced health and health effects of reduced income: implications for health-state valuation
    M J Sculpher
    Centre for Health Economics, University of York, Heslington, United Kingdom
    Med Decis Making 20:207-15. 2000
    ..The authors review the most popular utility systems regarding how these income effects are handled and assess the implications for the measurement of utilities using these systems...
  14. ncbi request reprint The cost-effectiveness of preference-based treatment allocation: the case of hysterectomy versus endometrial resection in the treatment of menorrhagia
    M Sculpher
    Health Economics Research Group, Brunel University, Uxbridge, UK
    Health Econ 7:129-42. 1998
    ..The clinical example used to explore these methods is the comparison of abdominal hysterectomy (AH) and transcervical resection of the endometrial (TCRE) for the treatment of menorrhagia...
  15. ncbi request reprint Modelling the long-term cost-effectiveness of endovascular or open repair for abdominal aortic aneurysm
    D M Epstein
    Centre for Health Economics, University of York, York, UK
    Br J Surg 95:183-90. 2008
    ..This study assessed the cost-effectiveness of EVAR...
  16. ncbi request reprint Screening for diabetic retinopathy: a relative cost-effectiveness analysis of alternative modalities and strategies
    M J Sculpher
    Health Economics Research Group, Brunel University, Uxbridge, Middlesex, UK
    Health Econ 1:39-51. 1992
    ....
  17. ncbi request reprint Generalisability in economic evaluation studies in healthcare: a review and case studies
    M J Sculpher
    Centre for Health Economics, University of York, UK
    Health Technol Assess 8:iii-iv, 1-192. 2004
    ..To review, and to develop further, the methods used to assess and to increase the generalisability of economic evaluation studies...
  18. ncbi request reprint The cost-effectiveness of an early interventional strategy in non-ST-elevation acute coronary syndrome based on the RITA 3 trial
    M Henriksson
    Centre for Health Economics, University of York, UK
    Heart 94:717-23. 2008
    ..Evidence suggests that an early interventional strategy for patients with non-ST-elevation acute coronary syndrome (NSTE-ACS) can improve health outcomes but also increase costs when compared with a conservative strategy...
  19. pmc Cost effectiveness of clinically appropriate decisions on alternative treatments for angina pectoris: prospective observational study
    S C Griffin
    Centre for Health Economics, University of York, York, USA
    BMJ 334:624. 2007
    ..To assess whether revascularisation that is considered to be clinically appropriate is also cost effective...
  20. ncbi request reprint The cost-effectiveness of etanercept and infliximab for the treatment of patients with psoriatic arthritis
    Y Bravo Vergel
    Centre for Health Economics, University of York, Heslington, YO10 5DD York, UK
    Rheumatology (Oxford) 46:1729-35. 2007
    ..We assess the cost-effectiveness of two TNF antagonists and so-called 'palliative care' for the treatment of active PsA from the perspective of the UK National Health Service (NHS)...
  21. doi request reprint The cost-effectiveness of adjuvant chemotherapy for early breast cancer: A comparison of no chemotherapy and first, second, and third generation regimens for patients with differing prognoses
    H E Campbell
    Health Economics Research Centre, University of Oxford, Headington, Oxford, United Kingdom
    Eur J Cancer 47:2517-30. 2011
    ..These adjuvant chemotherapy regimens were used in three large UK-led randomised controlled trials (RCTs)...
  22. ncbi request reprint A multicentre randomised controlled trial assessing the costs and benefits of using structured information and analysis of women's preferences in the management of menorrhagia
    A D M Kennedy
    Health Economics Research Group, Brunel University, Uxbridge, UK
    Health Technol Assess 7:1-76. 2003
  23. doi request reprint Quality of life, resource consumption and costs of spinal cord stimulation versus conventional medical management in neuropathic pain patients with failed back surgery syndrome (PROCESS trial)
    Andrea Manca
    Centre for Health Economics, Alcuin A Block, University of York, York YO10 5DD, United Kingdom
    Eur J Pain 12:1047-58. 2008
    ..Chronic back and leg pain conditions result in patients' loss of function, reduced quality of life and increased costs to the society...
  24. doi request reprint Identifying research priorities: the value of information associated with repeat screening for age-related macular degeneration
    Laura Bojke
    Centre for Health Economics, University of York, York, United Kingdom
    Med Decis Making 28:33-43. 2008
    ..This case study also illustrates the need to account for any structural uncertainties appropriately...
  25. ncbi request reprint A cost-utility analysis of tension-free vaginal tape versus colposuspension for primary urodynamic stress incontinence
    Andrea Manca
    Centre for Health Economics, University of York, UK
    BJOG 110:255-62. 2003
    ..To assess the cost effectiveness of tension-free vaginal tape compared with open Burch colposuspension as a primary treatment for urodynamic stress incontinence...
  26. pmc Value based pricing for NHS drugs: an opportunity not to be missed?
    Karl Claxton
    Centre for Health Economics, University of York, York
    BMJ 336:251-4. 2008
  27. ncbi request reprint Effects of decision aids for menorrhagia on treatment choices, health outcomes, and costs: a randomized controlled trial
    Andrew D M Kennedy
    Health Economics Research Group, Brunel University, Uxbridge, Middlesex, UB8 3PH England
    JAMA 288:2701-8. 2002
    ..Decision aids can increase patient involvement in treatment decision making. However, questions remain regarding their effects and cost implications...
  28. doi request reprint The cost-effectiveness of cotrimoxazole prophylaxis in HIV-infected children in Zambia
    Mairin Ryan
    National Centre for Pharmacoeconomics, Department of Pharmacology and Therapeutics, Trinity College, Dublin, Ireland
    AIDS 22:749-57. 2008
    ....
  29. ncbi request reprint Unfinished symphony: a tribute to the life and career of Bernie O'Brien (1959-2004)
    Andrew Briggs
    Centre for Health Economics, University of York, Heslington, York, United Kingdom
    Med Decis Making 24:538-44. 2004
    ..He was also an excellent communicator and teacher and, above all, a fun guy to work with. In this article, the authors provide a review of Bernie's academic contributions...
  30. ncbi request reprint Costs of an early intervention versus a conservative strategy in acute coronary syndrome
    David M Epstein
    Centre for Health Economics, University of York, Heslington, York, YO10 5DD, UK
    Int J Cardiol 127:240-6. 2008
    ..This paper uses data from the RITA-3 trial to compare the health service costs of the two strategies...
  31. ncbi request reprint Assessing generalisability by location in trial-based cost-effectiveness analysis: the use of multilevel models
    Andrea Manca
    Centre for Health Economics, University of York, UK
    Health Econ 14:471-85. 2005
    ....
  32. ncbi request reprint Using value of information analysis to prioritise health research: some lessons from recent UK experience
    Karl P Claxton
    Centre for Health Economics, University of York, York, England
    Pharmacoeconomics 24:1055-68. 2006
    ....
  33. ncbi request reprint Estimating mean QALYs in trial-based cost-effectiveness analysis: the importance of controlling for baseline utility
    Andrea Manca
    Centre for Health Economics, University of York, UK
    Health Econ 14:487-96. 2005
    ....
  34. ncbi request reprint Using value of information analysis to inform publicly funded research priorities
    Laura Ginnelly
    Centre for Health Economics, University of York, York, UK
    Appl Health Econ Health Policy 4:37-46. 2005
    ..The case study presented considers whether long-term, low-dose antibacterial treatment of recurrent urinary tract infections (UTIs) in children is effective and cost effective compared with short-term antibacterial therapy...
  35. ncbi request reprint Health-related quality of life after interventional or conservative strategy in patients with unstable angina or non-ST-segment elevation myocardial infarction: one-year results of the third Randomized Intervention Trial of unstable Angina (RITA-3)
    Joseph Kim
    Medical Statistics Unit, London School of Hygiene and Tropical Medicine, Keppel Street, London WC1E 7HT, UK
    J Am Coll Cardiol 45:221-8. 2005
    ..We sought to compare the effects of an early interventional strategy (IS) versus a conservative strategy (CS) on health-related quality of life (HRQOL) in patients with non-ST-segment elevation acute coronary syndromes (ACS)...
  36. pmc Assessing generalisability in model-based economic evaluation studies: a structured review in osteoporosis
    Hege Urdahl
    Merck Sharp and Dohme, Hertford, UK
    Pharmacoeconomics 24:1181-97. 2006
    ..Transparency of reporting is expected to increase as methodology develops and decision makers publish 'reference case' type guidance...
  37. ncbi request reprint Better analysis for better decisions: facing up to the challenges
    Michael F Drummond
    Pharmacoeconomics 24:1039-42. 2006